With its cardiovascular business growing roughly 20% the past several years, medtech giant Boston Scientific has had to scale. Two-thirds of the Massachusetts-based company’s net sales come from that business unit, based in Minnesota, so Joe Fitzgerald oversees much of the company’s growth. In October, a Maple Grove facility opened and another expanded. The company’s biggest accelerator in the past decade has been its Watchman stroke-prevention device, nearly a $2 billion business, Fitzgerald says. Farapulse, an ablation treatment acquired in 2021, has furthered growth, as has a new drug-coated balloon. The coming year is all about continuity with that core business, he says.